CRISPR Therapeutics AG (CRSP) Free Cash Flow: 2015-2025
Historic Free Cash Flow for CRISPR Therapeutics AG (CRSP) over the last 10 years, with Sep 2025 value amounting to -$84.7 million.
- CRISPR Therapeutics AG's Free Cash Flow rose 20.93% to -$84.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$303.1 million, marking a year-over-year decrease of 58.55%. This contributed to the annual value of -$144.7 million for FY2024, which is 46.39% up from last year.
- Per CRISPR Therapeutics AG's latest filing, its Free Cash Flow stood at -$84.7 million for Q3 2025, which was up 25.69% from -$114.0 million recorded in Q2 2025.
- CRISPR Therapeutics AG's Free Cash Flow's 5-year high stood at $780.4 million during Q2 2021, with a 5-year trough of -$151.6 million in Q2 2022.
- In the last 3 years, CRISPR Therapeutics AG's Free Cash Flow had a median value of -$84.7 million in 2025 and averaged -$60.7 million.
- In the last 5 years, CRISPR Therapeutics AG's Free Cash Flow surged by 2,473.12% in 2021 and then slumped by 155.23% in 2024.
- CRISPR Therapeutics AG's Free Cash Flow (Quarterly) stood at -$95.2 million in 2021, then dropped by 25.52% to -$119.5 million in 2022, then grew by 19.00% to -$96.8 million in 2023, then spiked by 48.06% to -$50.3 million in 2024, then grew by 20.93% to -$84.7 million in 2025.
- Its Free Cash Flow was -$84.7 million in Q3 2025, compared to -$114.0 million in Q2 2025 and -$54.2 million in Q1 2025.